Sorrento Therapeutics, Inc.
SRNE · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1,694 | $1,669 | $3,858 | $7,090 |
| - Cash | $69,749 | $37,655 | $23,634 | $70,686 |
| + Debt | $207,600 | $183,597 | $134,504 | $181,586 |
| Enterprise Value | $139,545 | $147,611 | $114,728 | $117,990 |
| Revenue | $15,025 | $16,251 | $15,594 | $17,400 |
| % Growth | -7.5% | 4.2% | -10.4% | – |
| Gross Profit | $6,572 | $11,065 | $1,872 | $9,132 |
| % Margin | 43.7% | 68.1% | 12% | 52.5% |
| EBITDA | -$99,483 | -$136,731 | -$204,927 | -$86,731 |
| % Margin | -662.1% | -841.4% | -1,314.1% | -498.5% |
| Net Income | -$95,212 | -$139,616 | -$223,692 | -$90,687 |
| % Margin | -633.7% | -859.1% | -1,434.5% | -521.2% |
| EPS Diluted | -0.17 | -0.26 | -0.51 | -0.2 |
| % Growth | 34.6% | 49% | -155% | – |
| Operating Cash Flow | -$55,659 | -$49,459 | -$68,338 | -$61,171 |
| Capital Expenditures | -$140 | -$86 | -$4,524 | -$3,835 |
| Free Cash Flow | -$55,799 | -$49,545 | -$72,862 | -$65,006 |